During her former role at a Magic Circle firm in London, Gina Bicknell assisted AstraZeneca in 2016 with its acquisition of the majority equity stake in Acerta Pharma, a privately-owned biopharmaceutical company based in the Netherlands and US. The acquisition provided AstraZeneca with rights to a potential best-in-class irreversible oral Bruton’s tyrosine kinase inhibitor, acalabrutinib, currently in Phase II/III development for B-cell blood cancers and in Phase I/II clinical trials in multiple solid tumours
Advice on Trademark licenses
Advice on Intellectual Property licensing issues related to insolvency
A manufacturer of industrial vehicles instructed our Dispute Resolution team to help terminate a contract it had made with another company to co-design and build 250 industrial vehicles.
We were recently instructed to act for software development company, to defend the alleged infringement of another company’s intellectual property rights.
We were instructed in relation to a trade mark dispute by a fashion house, which designs and sells bespoke menswear.
Our client works with many plant breeders to maximise the commercial exploitation of their plant variety rights, exploring opportunities with, and granting sub-licences to, many overseas fruit and vegetable growers.
Our client is a direct marketing and digital agency that specialises in e-bulletins.
Our client had been approached by the owner of a patent which related to golf equipment and, following their initial discussions, our client identified an opportunity for it to exploit the patent commercially by manufacturing and distributing a new golf-related product.
Our client supplies plant-based products and, working in collaboration with a research group at a University, our client was looking to develop new products for commercial exploitation.